Evidence map›Paper›PMID 27176798›Full record

Trial reportBlood cancer journal2016

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.

P S Becker, T A Gooley, D J Green, N Burwick, T Y Kim, K Kojouri, Y Inoue, D J Moore, E Nelli, T Dennie and 1 more

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

P S BeckerDivisions of Hematology and Medical Oncology, University of Washington, Seattle, WA, USA.
T A GooleyDivisions of Hematology and Medical Oncology, University of Washington, Seattle, WA, USA.
D J GreenDivisions of Hematology and Medical Oncology, University of Washington, Seattle, WA, USA.
N BurwickDivisions of Hematology and Medical Oncology, University of Washington, Seattle, WA, USA.
T Y KimSkagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA, USA.
K KojouriSkagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA, USA.
Y InoueProvidence Regional Cancer Partnership, Everett, WA, USA.
D J MooreSeattle Cancer Care Alliance, Seattle, WA, USA.
E NelliHematology Oncology Associates, Medford, OR, USA.
T DennieMultiCare Health System, Tacoma, WA, USA.
W I BensingerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibCyclophosphamideDexamethasoneDoxorubicinFemaleHumansMaleMiddle AgedMultiple MyelomaNeoadjuvant TherapyPolyethylene GlycolsRecurrenceBortezomibCyclophosphamideDexamethasoneDoxorubicinliposomal doxorubicinPolyethylene Glycols

Identifiers

PMID27176798
PMCPMC4916300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.